Mercury Bio, a biotechnology company based in Santa Fe, NM, has recently become a charter member of the Alliance for mRNA Medicines (AMM), a notable global organization dedicated to advancing mRNA and next-generation encoding RNA therapeutics and vaccines. Additionally, Dr. Richard Sayre, Chief Science Officer at Mercury Bio, has joined the AMM board.

Expressing enthusiasm about the new addition, Clay Alspach, Executive Director of AMM, stated, "We are excited to welcome Mercury Bio to our esteemed community of leading biotech companies, pharmaceutical firms, academic institutions, and non-profit organizations committed to advancing the field of mRNA medicines. We anticipate valuable scientific contributions from Mercury Bio as we collectively strive to make novel nucleic acid therapeutics widely accessible."

Bruce McCormick, CEO of Mercury Bio, emphasized the success of their drug delivery platform, showcasing effective oral and IV delivery of nucleic acids throughout the body, including the brain. The platform, known as yeast-derived extracellular vesicles (yEV™), is a proprietary, non-animal, and non-human alternative to lipid nanoparticles (LNP). Dr. Sayre leads a scientific team with expertise in exosomes, microbial genetics, molecular and computational biology, and bioinformatics. McCormick expressed excitement about the collaboration with AMM, highlighting their joint efforts to advance novel nucleic acid therapeutics.

The Alliance for mRNA Medicines (AMM) is a leading global organization dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines. Their mission is to drive the future of mRNA medicine, improve patients' lives, and advance scientific knowledge by bringing together and empowering leaders, innovators, scientists, and key stakeholders in the mRNA industry. 

 

Source: prnewswire.com

Report Abuse